Exploring the Role of Artificial Intelligence in Mental Healthcare: Progress, Pitfalls, and Promises.

The rise of artificial intelligence (AI) heralds a significant revolution in healthcare, particularly in mental health. AI's potential spans diagnostic algorithms, data analysis from diverse sources, and real-time patient monitoring. It is essential for clinicians to remain informed about AI's progress and limitations. The inherent complexity of mental disorders, limited objective data, and retrospective studies pose challenges to the application of AI. Privacy concerns, bias, and the risk of AI replacing human care also loom. Regulatory oversight and physician involvement are needed for equitable AI implementation. AI integration and use in psychotherapy and other services are on the horizon. Patient trust, feasibility, clinical efficacy, and clinician acceptance are prerequisites. In the future, governing bodies must decide on AI ownership, governance, and integration approaches. While AI can enhance clinical decision-making and efficiency, it might also exacerbate moral dilemmas, autonomy loss, and issues regarding the scope of practice. Striking a balance between AI's strengths and limitations involves utilizing AI as a validated clinical supplement under medical supervision, necessitating active clinician involvement in AI research, ethics, and regulation. AI's trajectory must align with optimizing mental health treatment and upholding compassionate care.

Buprenorphine Extended-Release Treatment for Opioid Use Disorder in the Postpartum Period.

Buprenorphine extended-release (XR) is an extended-release monthly injection to treat opioid use disorder (OUD). This retrospective case series includes 15 postpartum patients who were treated with buprenorphine-XR at a single center and reports on their outcomes. The average total daily sublingual buprenorphine dose before initiation of buprenorphine-XR was 16.25 mg (SD±7.76, range 2-32 mg). Overall, 137 total doses of buprenorphine-XR were administered between May 17, 2021, and April 11, 2023. Urine toxicology test results were negative for opioids other than buprenorphine in the majority (80.0%) of patients once appropriate maintenance doses were achieved. Euphoria and intoxication were not reported. A minority of patients (20.0%) discontinued buprenorphine-XR. Although more extensive research is needed before widespread use, buprenorphine-XR may be a favorable treatment for OUD in this high-risk population.

From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.

Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in or after the year 1990 which examined one or more gene-drug interactions for smoking cessation treatment. Out of 644 citations, 46 articles met the inclusion criteria for the systematic review. We summarize evidence on several genetic polymorphisms (CHRNA5-A3-B4, CYP2A6, DBH, CHRNA4, COMT, DRD2, DRD4 and CYP2B6) and their potential moderating pharamacotherarpy effects on patient cessation efficacy rates. These findings are promising and call for further research to demonstrate the effectiveness of genetic testing in personalizing treatment decision-making and improving outcome.